NCT04562090View on ClinicalTrials.gov

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

PHASE4CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

March 17, 2022

Study Completion Date

March 30, 2022

Conditions
Urge IncontinenceOveractive Bladder (OAB)
Interventions
DRUG

mirabegron

Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet

Trial Locations (15)

Unknown

Site CN86020, Wuhan

Site CN86001, Beijing

Site CN86004, Beijing

Site CN86014, Beijing

Site CN86010, Chengdu

Site CN86009, Guangzhou

Site CN86018, Guangzhou

Site CN86003, Lanzhou

Site CN86013, Shanghai

Site CN86002, Suzhou

Site CN86021, Taiyuan

Site CN86011, Wuhan

Site CN86022, Wuxi

Site CN86012, Xi'an

Site CN86007, Zhengzhou

All Listed Sponsors
lead

Astellas Pharma China, Inc.

INDUSTRY

NCT04562090 - A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder | Biotech Hunter | Biotech Hunter